PMH 9907: Long‐term outcomes of a randomized phase 3 study of short‐term bicalutamide hormone therapy and dose‐escalated external‐beam radiation therapy for localized prostate cancer

CONCLUSIONSFor patients who predominantly have IRPC, the addition of HT to DE‐EBRT did not significantly affect BF, OS, or LC. Bicalutamide appeared to be well tolerated. The conclusions from the study are limited by incomplete recruitment. Cancer 2016. © 2016 American Cancer Society.

Source: Cancer - May 23, 2016 Category: Cancer & Oncology Authors: Andrew J. McPartlin, Rachel Glicksman, Melania Pintilie, Debbie Tsuji, Gary Mok, Andrew Bayley, Peter Chung, Robert G. Bristow, Mary K. Gospodarowicz, Charles N. Catton, Michael Milosevic, Padraig R. Warde Tags: Original Article Source Type: research